Background of the KEYLYNK-007 trial for advanced solid tumours

Bookmark and Share
Published: 13 Jun 2020
Views: 216
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

Dr Timothy Yap talks to ecancer in an online interview for the ASCO virtual meeting 2020 about the KEYLYNK-007 trial, a phase 2 trial of the PARP inhibitor olaparib in combination with the PD-1 inhibitor pembrolizumab in patients with previously treated advanced solid tumours with homologous recombination repair mutations (HRRm) and/or homologous recombination repair deficiency (HRD).

Dr Yap outlines the trial design, and the reasons behind choosing olaparib in combination with pembrolizumab.

He also discusses how it could personalise treatment in the future.